News
06-06-2020, 07:10 PM
In 2017 and 2019, the German Institute for Quality and Efficiency in Health Care had already examined the advantages and disadvantages of ribociclib in combination with an aromatase inhibitor or fulvestrant in comparison with the appropriate comparator therapy in patients after menopause, with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.
More... (https://www.news-medical.net/news/20200605/Newer-data-confirms-survival-advantages-but-also-side-effects-for-ribociclib-in-breast-cancer.aspx)
More... (https://www.news-medical.net/news/20200605/Newer-data-confirms-survival-advantages-but-also-side-effects-for-ribociclib-in-breast-cancer.aspx)